Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study

IMPORTANCE: The development of new primary cutaneous melanoma (CM) after starting immune checkpoint inhibitor (ICI) therapy is poorly characterized. OBJECTIVE: To determine the incidence of new CM in patients treated with ipilimumab, nivolumab, and/or pembrolizumab for metastatic melanoma. DESIGN, S...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Dermatol
Autores principales: Nanda, Japbani K., Dusza, Stephen W., Navarrete-Dechent, Cristian, Liopyris, Konstantinos, Marghoob, Ashfaq A., Marchetti, Michael A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2021
Materias:
Brief Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7495326/
https://ncbi.nlm.nih.gov/pubmed/32936222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2020.3671
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares